Investment Analysts’ Recent Ratings Changes for GH Research (GHRS)

Several analysts have recently updated their ratings and price targets for GH Research (NASDAQ: GHRS):

• 1/23/2026 – GH Research had its price target raised by analysts at Royal Bank Of Canada from $33.00 to $40.00. They now have an “outperform” rating on the stock.
• 1/22/2026 – GH Research had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 1/6/2026 – GH Research was given a new $29.00 price target on by analysts at Needham & Company LLC.
• 1/6/2026 – GH Research had its price target raised by analysts at Canaccord Genuity Group Inc. from $35.00 to $39.00. They now have a “buy” rating on the stock.
• 1/6/2026 – GH Research was given a new $39.00 price target on by analysts at Wolfe Research.
• 1/6/2026 – GH Research had its “market outperform” rating reaffirmed by analysts at Citigroup Inc..
• 1/5/2026 – GH Research had its “buy” rating reaffirmed by analysts at TD Cowen.
• 1/5/2026 – GH Research had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $29.00 price target on the stock.
• 1/5/2026 – GH Research had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $19.00 price target on the stock.

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.